Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Lazarus who wrote (57829)	8/19/2016 1:10:53 PM
From: E_K_S	Read Replies (2) \| Respond to of 78702

Maybe McDonalds needed to use their services to test their new fitbit private label step tracking toy. I guess they were recalled as the products (part of the free toy in their kid's meal) was causing skin irritation. Will put IVRO on my micro-cap watch list. EKS

To: Lazarus who wrote (57829)	9/14/2017 12:24:50 PM
From: Lazarus	Respond to of 78702

Some selling came in on this one today so I managed to get some .03 shares for my IRA. I think the reason this stock is getting some attention is it UPLISTED to the OTC Pink Sheets. This note in their quarterly report is interesting: "As explained in Note 6 to the financial statements, as of October 1, 2014, the Company’s accumulated deficit of $24,556,683 was restated to zero and its common stock account was reduced by the same amount from $25,166,313 to $609,630. This readjustment of the accumulated deficit and reclassification of the capital account is known as a quasi-reorganization or accounting restructuring and is permitted under US GAAP pursuant to Accounting Standards Codification (“ASC”) 852-20-25. Most of the accumulated deficit occurred prior to 1994. To implement the quasir-eorganization, the Company had to show through financial results or modified operations that it had fully recovered from the years when the deficit was incurred and that it had obtained approval of the restructuring from its board of directors and shareholders. 3 The Company’s prior management was replaced and the management structure reorganized from 1995 through 1999. New management modified the Company’s prior operational strategy and from October 1, 2009 to September 30, 2014, the Company had five consecutive fiscal years of profitable operations. As a result, the Board of Directors determined that the Company had met the requirements of ASC 852-20-25 and the quasi-reorganization was made effective as of October 1, 2014. The Company remained profitable in fiscal 2015 and 2016."

To: Lazarus who wrote (57829)	9/19/2017 1:55:31 PM
From: Investor Clouseau	Read Replies (3) \| Respond to of 78702

do you still like IVRO at it's current price? yahoo shows it now has a p/e of 8.

To: Lazarus who wrote (57829)	9/19/2017 2:50:26 PM
From: Lazarus	1 Recommendation Recommended By Investor Clouseau Respond to of 78702

Yes, as I mentioned here the other day, I added 30k shares on the dip to .03 It has a lot of the elements I look for in a good penny stock: Many years in business The last 7 years have been profitable Simple stock structure with no preferreds and no dilution. The recent uplisting to the OTC Pink Sheets I consider very positive. Now its just a matter of time.

To: Lazarus who wrote (57829)	12/4/2019 1:05:12 PM
From: Lazarus	Respond to of 78702

INVITRO INTERNATIONAL ANNOUNCES ADOPTION OF ITS CORE TECHNOLOGY OCULAR IRRITECTION®, OECD TG SOURCE 496 December 3, 2019, Placentia, CA. Today InVitro International (OTC Market, IVRO) announced that Ocular Irritection® (OI) is now adopted by OECD (Organization for Economic Cooperation and Development) and available for immediate use globally under Test Guideline (TG 496). OI is the first 100% animal free ocular irritancy test method to be adopted by OECD and its 36 member countries representing about 80% of global trade, including the United States. This adoption culminates an 11 year effort with OECD which is viewed as the world’s foremost Regulatory body for in vitro test methods. OI is part of IVRO’s 28 year old Irritection® Assay System (IAS), along with companion test method Irritection® Dermal that tests for skin irritancy. IVRO CEO, W. Richard Ulmer, commented on OI’s new globally accepted status, “It has been a lengthy, yet very rewarding process to gain OECD final adoption. In 1985 IVRO pioneered 100% cruelty free test methods when there was not even one specific regulatory body to set standards or approve test methods anywhere in the world. Now 35 years later, OECD adoption represents the highest scientific review level for any non-animal test method.” New IVRO President, Atul Jhalani, added: “In our minds, OECD’s (TG 496) OI adoption provides IVRO’s Irritection® technology fresh legal and scientific credibility. With Corrositex® (2006), we now have two commercialized in vitro test methods that are globally accepted. It is our plan to re-launch OI as a unique test method, featuring its lowest cost, fastest results, simplest to use and install characteristics. We are excited that supporting our efforts will be U.S. states CA, IL, and several others banning the introduction of new cosmetics starting in 2020, if they or their ingredients were tested on animals. And the same Federal legislation is now pending before Congress. Furthermore, we believe that large cosmetics markets such as Brazil & Colombia plan to follow India, Taiwan and others with a similar ban very soon. It appears to us and many others that in vitro testing has a very bright future at the expense of animal testing.” __________ closing price on day of 8/19/2016 post was .02 cents 4 BAGGER SO FAR